Last reviewed · How we verify
High severity group: Escitalopram
Escitalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Escitalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.
At a glance
| Generic name | High severity group: Escitalopram |
|---|---|
| Also known as | Lexapro, Selective serotonin reuptake inhibitor (SSRI) |
| Sponsor | University of Texas Southwestern Medical Center |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Escitalopram is the active S-enantiomer of citalopram and works as a selective serotonin reuptake inhibitor (SSRI). By blocking the serotonin transporter protein, it prevents the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons, thereby increasing serotonin concentration and enhancing neurotransmission. This mechanism is thought to improve mood and reduce anxiety symptoms in psychiatric disorders.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Panic disorder
- Social anxiety disorder
- Obsessive-compulsive disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Somnolence
- Sexual dysfunction
- Diarrhea
- Dry mouth
- Sweating
Key clinical trials
- Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial (NA)
- Antidepressant Treatment at an Inner City Asthma Clinic (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: